At the news
? BULLISHIMPACT 7/10 6-K filed Jun 25, 2026 at 06:06 ET
HUTCHMED reported pivotal Phase II data for fanregratinib in FGFR2-fusion intrahepatic cholangiocarcinoma, showing a 42.5% ORR (primary endpoint met) and a manageable safety profile. The NDA has already been accepted with priority review by China's NMPA since December 2025, de-risking the regulatory path. This is a clear positive catalyst for a mid-cap biotech with an 88% bullish analyst consensus.
- Phase II registration trial (NCT04353375) met primary endpoint: IRC-assessed ORR of 42.5% (95% CI: 30.0%-53.6%)
- Median progression-free survival (PFS) of 6.9 months; median overall survival (OS) of 16.6 months
- Disease control rate (DCR) of 83.9% (95% CI: 74.5%-90.9%)
- NDA for fanregratinib in advanced ICC accepted and granted priority review by China NMPA in December 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access